Responsive polymersomes enhance the action of STING-targeting cyclic dinucleotides in cancer therapy.
Access options
Subscribe to Journal
Get full journal access for 1 year
$169.00
only $14.08 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
from$8.99
All prices are NET prices.

References
- 1.
Adams, D. et al. N. Engl. J. Med. 379, 11–21 (2018).
- 2.
Coelho, T. et al. N. Engl. J. Med. 369, 819–829 (2013).
- 3.
Shae, D. et al. Nat. Nanotechnol. https://doi.org/10.1038/s41565-018-0342-5 (2019).
- 4.
Chen, Q., Sun, L. & Chen, Z. J. Nat. Immunol. 17, 1142–1149 (2016).
- 5.
Ablasser, A. et al. Nature 498, 380–384 (2013).
- 6.
Corrales, L., McWhirter, S. M., Dubensky, T. W. & Gajewski, T. F. J. Clin. Invest. 126, 2404–2411 (2016).
- 7.
Woo, S.-R. et al. Immunity 41, 830–842 (2014).
- 8.
Corrales, L. et al. Cell Rep. 11, 1018–1030 (2015).
- 9.
Fu, J. et al. Sci. Transl. Med. 7, 283ra52 (2015).
- 10.
Foote, J. B. et al. Cancer Immunol. Res. 5, 468–479 (2017).
- 11.
Hanson, M. C. et al. J. Clin. Invest. 125, 2532–2546 (2015).
- 12.
Koshy, S. T., Cheung, A. S., Gu, L., Graveline, A. R. & Mooney, D. J. Adv. Biosyst. 1, 1600013 (2017).
- 13.
Manganiello, M. J., Cheng, C., Convertine, A. J., Bryers, J. D. & Stayton, P. S. Biomaterials 33, 2301–2309 (2012).
Author information
Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Hubbell, J.A., Swartz, M.A. Trojan horses for immunotherapy. Nat. Nanotechnol. 14, 196–197 (2019). https://doi.org/10.1038/s41565-019-0380-7
Published:
Issue Date:
Further reading
-
Co-delivery of Peptide Neoantigens and Stimulator of Interferon Genes Agonists Enhances Response to Cancer Vaccines
ACS Nano (2020)
-
Amphiphilic Polyelectrolyte Graft Copolymers Enhance the Activity of Cyclic Dinucleotide STING Agonists
Advanced Healthcare Materials (2020)
-
Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma
Journal for ImmunoTherapy of Cancer (2020)